Sanofi's Rilzabrutinib Granted Orphan Drug Designation In The U.S. For Two Rare Diseases
April 3 (Reuters) - Sanofi SA SASY.PA:
PRESS RELEASE: RILZABRUTINIB GRANTED ORPHAN DRUG DESIGNATION IN THE US FOR TWO RARE DISEASES WITH NO APPROVED MEDICINES
FDA TARGET ACTION DATE FOR ITP DECISION IS AUGUST 29, 2025
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Tesla Q1 2026 Earnings Preview: 50,000-Unit Inventory Overhang, Energy Storage Halved, 5 Core Metrics Long-Term Investors Should Really Watch

Asia-Pacific Stocks Rise Across the Board Monday as Easing Middle East Tensions Boost Market Sentiment

AST SpaceMobile Shares Plunge in Overnight Trading, What Happened? Will It Affect SpaceX?

Meme Stocks Reappear. Avis Shares Reach New Highs Amid Short Squeeze. Can Retail Investors Still Buy?

Intel Stock Has Surged 74% in 2026 and Earnings Land April 23 — Is INTC Still a Buy at $68?

Tradingkey






